Ovid Therapeutics Inc. (OVID)

Every figure this model derived for OVID, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 117,219,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 123,617,000 AssetsCurrent 2026-06-30
current liabilities 9,980,000 LiabilitiesCurrent 2026-06-30
equity 209,890,000 StockholdersEquity 2026-06-30
ocf -54,773,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,583,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 4,781,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up OVID on one particular measure came for.

RatioValue
current ratio12.39
current ratio reported12.39
deferred revenue growth-100.0
growth cv1.35
revenue growth-76.2
revenue growth per share-76.2
roic-49.75
rule of 40-3762.87
sbc pct revenue302.02

What to be careful about

What this model itself distrusts about OVID's figures. Written by the derivation as it ran, not added afterwards.